Intellia Therapeutics NTLA Cash Flow Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| —— | -$96.23M-0.5% | -$95.79M+5.5% | -$101.32M-0.1% | -$101.26M+11.4% | ||
| —— | $2.2M-7.5% | $2.38M-0.8% | $2.4M-4.0% | $2.5M+0.1% | ||
| —— | $13.48M-19.5% | $16.74M-14.6% | $19.6M-11.0% | $22.04M+0.9% | ||
| —— | -$337K— | —— | —— | $849K-57.3% | ||
| —— | -$1.42M-120% | $6.96M+101% | $3.46M+235% | -$2.56M-37.1% | ||
| —— | -$11.95M— | —— | -$715K— | —— | ||
| —— | $12.97M+49.3% | $8.69M-62.3% | $23.04M+547% | -$5.16M-2,265% | ||
| —— | -$6.66M+52.4% | -$13.98M-185% | -$4.91M-18.8% | -$4.13M+19.0% | ||
| —— | -$904K+65.9% | -$2.65M-177% | $3.44M+157% | $1.34M+163% | ||
| —— | -$117.35M-69.4% | -$69.29M+9.9% | -$76.9M+22.8% | -$99.62M+33.1% | ||
| —— | $79K-37.3% | $126K+334% | $29K-87.9% | $239K-67.5% | ||
| —— | $66.31M+141% | $27.53M— | $0-100% | $106.91M+13.3% | ||
| $194.6M— | —— | $128.08M+131,939% | $97K— | $0— | ||
| —— | $33.57M+1,598% | $1.98M-98.3% | $114.86M+684% | $14.65M— | ||
| —— | -$17.47M+56.1% | -$39.77M-207% | $37.22M— | —— | ||
| —— | $535K-35.2% | $826K-23.9% | $1.09M-34.9% | $1.67M-26.9% | ||
| —— | -$904K+65.9% | -$2.65M-177% | $3.44M+157% | $1.34M+163% | ||
| —— | -$12.84M-177% | -$4.64M-0.2% | -$4.63M+72.2% | -$16.66M+42.6% | ||
| —— | -$8.41M-1.4% | -$8.29M+4.0% | -$8.64M+3.3% | -$8.93M-23.8% | ||
| —— | $74K+104% | -$1.94M+92.3% | -$25.29M-339% | $10.59M-23.4% | ||
| —— | $12.97M+49.3% | $8.69M-62.3% | $23.04M+547% | -$5.16M-2,265% | ||
| —— | $0-100% | $32K— | $0+100% | -$82K-200% | ||
| —— | -$6.66M+52.4% | -$13.98M-185% | -$4.91M-18.8% | -$4.13M+19.0% | ||
| —— | —— | $0— | $0— | $0— | ||
| —— | $0— | —— | —— | —— | ||
| —— | -$117.43M-69.2% | -$69.41M+9.8% | -$76.93M+23.0% | -$99.86M+33.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Intellia Therapeutics generate?
- Intellia Therapeutics (NTLA) generated -$363.2M in operating cash flow over the trailing twelve months.
- What is Intellia Therapeutics's free cash flow?
- After $473.0K of capital expenditures, Intellia Therapeutics's free cash flow was -$363.6M over the trailing twelve months, up 4.6% year over year.
- Where does Intellia Therapeutics's cash flow data come from?
- Every line is extracted from Intellia Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
